The Question Biotech Companies and Investors Ask Too Late — and It's Costing Them Billions

The Industry Is Asking the Right Questions in the Wrong Order

Most biotech failures aren't scientific failures.

They're adoption failures that were entirely predictable — and almost nobody asked the right question early enough to see them coming.

There are four questions every biotech investor asks:

1. Will it work?

2. Will it get approved?

3. Will it get reimbursed?

4. Will it get adopted?

Every CEO knows they need credible answers to all four. The problem isn't the questions. It's the sequence in which they’re asked.

The Conversation That Crystallized This

I was speaking with a biotech CEO last week. Smart. Disciplined. Focused.

He said: "We have limited capital, so we're prioritizing the clinical trials that get us to approval. Then we'll bring in reimbursement experts."

It's logical. It's how most companies are built.

It's also where many go quietly off track.

Because there's a harder question underneath all four — one investors will see immediately, even if the CEO hasn't asked it yet:

If physicians won't change their prescribing behavior. If patients don't perceive meaningful benefit over what already exists. Approval won't fix that. Reimbursement won't rescue it. No amount of post-launch commercial spending can manufacture adoption for an undifferentiated product.

The science can be flawless. The approval can be clean. The launch can still fail. Wouldn’t you want to know that answer before investing in an expensive and lengthy clinical trial program?

Why This Matters More Now

M&A is the primary exit in today's market. That changes everything about how assets get valued.

Strategic buyers aren't just asking "Will it work?" They've been burned too many times by products that worked scientifically and failed commercially. They're now asking a different question in diligence:

That's an adoption question. And they're asking it earlier than most CEOs expect.

The companies commanding premium valuations — the ones actually getting bought — are the ones that can demonstrate adoption evidence before Phase 3, not explain adoption disappointment after launch.

The Question Sequence Needs to Flip—What’s Last Needs to Go First

Here's what the framework should actually look like:

1. Will it get adopted? Is the product sufficiently differentiated and valued in the real world?

2. Will it work? Does the clinical evidence support that differentiation?

3. Will it get approved? Can you build a regulatory path around actual use cases?

4. Will it get reimbursed? Does the value story hold for payers?

Starting with adoption doesn't mean ignoring science. It means letting commercial reality shape how you pursue the science — which indications to prioritize, which endpoints matter, which comparators are clinically and commercially relevant.

It means building a company that can be acquired, not just approved.

The Capital Objection — and Why It No Longer Holds

The predictable pushback: "We don't have the capital to answer that question this early."

That used to be a fair argument. It isn't anymore.

Early-stage adoption assessment doesn't require the cost and timeline of traditional commercial research. Frameworks like RAMPx (Realistic Assessment of Market Potential) are designed to give leadership teams an objective, directional read on adoption risk — at a fraction of the cost, and early enough to actually influence clinical development strategy.

Not a perfect answer. A directional one. Think of it as a stress test for your most important assumption.

If the early signal on adoption is positive — you validate your hypothesis, sharpen clinical strategy around what will actually drive use, and tell a more credible story to investors and acquirers.

If the early signal raises concerns — you find out now, when you can still course correct, not after you've spent $200M proving something the market didn't actually need.

The Bottom Line

Smart investors and strategic buyers are already asking the adoption question first. The CEOs who get ahead of that — who treat adoption as a scientific and strategic variable, not a commercial afterthought — are the ones who will build companies worth acquiring.

The question isn't whether the market will eventually demand this rigor.

It already does.